FDA Approved: BENLYSTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves a supplemental application for Benlysta (belimumab) filed by GlaxoSmithKline, resulting in an update to the product’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• BENLYSTA (belimumab)

Snippet

SUPPL AP for BENLYSTA (BELIMUMAB)